Overview
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Status:
Completed
Completed
Trial end date:
2014-12-19
2014-12-19
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AllerganTreatments:
Bimatoprost
Cloprostenol
Timolol
Criteria
Inclusion Criteria:- Diagnosed with primary open-angle glaucoma or ocular hypertension
- Previously prescribed intraocular pressure (IOP)-lowering medication with insufficient
IOP control and is now being switched to GANFORT® UD for medical reasons
Exclusion Criteria:
- None